High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.
Muchtar E et al. Leuk Lymphoma. 2016 Oct 13:1-14. [Epub ahead of print].
Is the revised International staging system for myeloma valid in a real world population?
Walker I et al. Br J Haematol. 2016 Oct 13. doi: 10.1111/bjh.14341. [Epub ahead of print].
Progress in Myeloma – A Monoclonal Breakthrough.
Rajkumar SV et al. N Engl J Med. 2016 Oct 6;375(14):1390-1392.
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.
Rajkumar SV et al. Blood. 2016 Oct 14. pii: blood-2016-09-692947. [Epub ahead of print].
The Rising Price of Cancer Drugs-A New Old Problem?
Prasad V et al. JAMA Oncol. 2016 Oct 6. doi: 10.1001/jamaoncol.2016.4275. [Epub ahead of print].
The role of maintenance therapy in multiple myeloma.
Lipe B et al. Blood Cancer J. 2016 Oct 21;6(10):e485. doi: 10.1038/bcj.2016.89.
The T Cell in Myeloma.
Joshua D et al. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):537-542. doi: 10.1016/j.clml.2016.08.003.
Panobinostat for the management of multiple myeloma.
Sivaraj D et al. Future Oncol. 2016 Oct 25. [Epub ahead of print].
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.
San-Miguel JF et al. Adv Ther. 2016 Sep 27. [Epub ahead of print].
Towards Stratified Medicine in Plasma Cell Myeloma.
Egan P et al. Int J Mol Sci. 2016 Oct 21;17(10). pii: E1760.
MGUS to myeloma: a mysterious gammopathy of underexplored significance.
Dhodapkar MV. Blood. 2016 Oct 13. pii: blood-2016-09-692954. [Epub ahead of print].
Vertigo and deafness: The sole presenting feature of multiple myeloma.
Rakul Nambiar K et al. J Egypt Natl Canc Inst. 2016 Oct 19. pii: S1110-0362(16)30056-5. doi: 10.1016/j.jnci.2016.09.001. [Epub ahead of print].
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) role in hematopoiesis and in hematologic diseases: A critical review.
Fracchiolla NS et al. Toxicology. 2016 Oct 17. pii: S0300-483X(16)30243-8. doi: 10.1016/j.tox.2016.10.007. [Epub ahead of print].
Mortality in a combined cohort of uranium enrichment workers.
Yiin JH et al. Am J Ind Med. 2016 Oct 18. doi: 10.1002/ajim.22668. [Epub ahead of print].
Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review.
Husnain M et al. Case Rep Oncol Med. 2016;2016:2490168. Epub 2016 Sep 26.
Daratumumab improves survival in multiple myeloma.
Baker H. Lancet Oncol. 2016 Oct 13. pii: S1470-2045(16)30503-4. doi: 10.1016/S1470-2045(16)30503-4. [Epub ahead of print].
Text mining electronic hospital records to automatically classify admissions against disease: Measuring the impact of linking data sources.
Kocbek S et al. J Biomed Inform. 2016 Oct 11. pii: S1532-0464(16)30141-1. doi: 10.1016/j.jbi.2016.10.008. [Epub ahead of print].
Pre-transplant bone marrow myeloma cells: less is better.
Manasanch EE.Leuk Lymphoma. 2016 Sep 29:1-2. [Epub ahead of print].
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
Jurczyszyn A et al. Br J Haematol. 2016 Sep 29. doi: 10.1111/bjh.14328. [Epub ahead of print].